库普罗托斯参与了c-Myc介导的乳腺癌干性
Runtian Wang1, Kun Xu1, Qin Chen1
1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Journal of translational medicine
|June 23, 2023
概括
瘤基因c-Myc与乳腺癌干和细胞死亡的一种形式cuproptosis相关. 这一发现为使用基于铜的疗法向异质瘤提供了新的途径.
科学领域:
- 在瘤学瘤学.
- 癌症干细胞生物学
- 分子生物学分子生物学
背景情况:
- 瘤内异质性 (ITH) 是由癌症干细胞 (CSC) 驱动的关键癌症特征.
- 了解调节瘤内干性的因素对于癌症治疗至关重要.
- 一种瘤基因c-Myc在乳腺癌等癌症中经常过度表达,并且可能与乳腺癌干细胞 (BCSCs) 联系起来.
研究的目的:
- 为了研究c-Myc和乳腺癌干细胞 (BCSC) 表型之间的相关性.
- 探索c-Myc,癌症干性和乳腺癌中质亡之间的关系.
- 确定用于预测乳腺癌临床结果的生物标志物.
主要方法:
- 免疫组织化学 (IHC) 染色对60个乳腺癌样本进行了c-Myc,CD44,CD24,CD133和ALDH1A1.1.的染色.
- 用生物信息学方法分析了1533名乳腺癌患者的转录组数据.
- 进行了相关性分析,将c-Myc,茎性标记物和与cuproptosis相关的基因联系起来.
主要成果:
- IHC证实了c-Myc表达和BCSC表型之间的正相关性.
- 生物信息分析显示,c-Myc,癌症干和cuproptosis之间存在显著的关联.
- 与cuproptosis相关的特征被确定为不良临床结果的预测因素,并且与MYC向丰富瘤中的癌症干具有积极的相关性.
结论:
- 在乳腺癌中,c-Myc与茎状和型亡有显著的相关性.
- 瘤前性cuproptosis生物标志物显示与癌症干的积极关联.
- 结果表明,基于铜的纳米材料在向异质乳腺瘤方面具有潜力.
相关概念视频
Induced Pluripotent Stem Cells
4.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.2K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Cancers Originate from Somatic Mutations in a Single Cell
12.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.1K


